Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

For that reason, among others, not everyone is buying what EKGuard has to sell. “Patients who are worried enough to call someone because they’re having chest symptoms really need to be seen by a physician, and been seen in an emergency room,” says Richard Stein, MD, a spokesperson for the American Heart Association (AHA) and a cardiologist at Beth Israel Medical Center in New York City.

Stein argues that a normal EKG doesn’t always carry enough information for a doctor to know whether there’s cause for concern. “Somewhere between 20 percent of men and 25 percent of women have symptoms during a heart attack that aren’t classic,” he says, adding that early EKGs don’t necessarily show telltale signs. Often, additional EKGs and blood tests are needed in order to rule out a heart attack, says Stein.

“I don’t think that the assurance EKGuard can give is one I would want my patients to have,” Stein says.

Lichtenstein, however, thinks that many of the people who might purchase his product and phone the call center are the type who might otherwise do nothing at all. “Research by the AHA has found that people just won’t call 911” during possible cardiac emergencies, Lichtenstein says. But he believes they will call EKGuard.

EKGuard will be available in five to eight more states within a year, and nationwide by 2010, Lichtenstein says.

Meanwhile, the medical community has yet to pass judgment on handheld EKG units. Stein and others would like to see the results of clinical trials before they give their endorsement; while many others seem optimistic, given the technology’s success in other countries.

If the service saves someone’s life, the steep startup cost will seem like a small price to pay, of course. On the other hand, if EKGuard creates a false sense of security for those who should instead be racing to an emergency room, cardiologists may not be quick to embrace it.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me